Related Experiment Video

Updated: Jul 5, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

Elizabeth M Swisher1, Wataru Sakai, Beth Y Karlan

  • 1Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA.

Cancer Research
|April 17, 2008
PubMed

Insights

Secondary BRCA1 mutations can cause platinum resistance in ovarian cancer. These genetic changes restore BRCA1 protein function, enabling resistant tumors to evade platinum-based chemotherapy.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Ovarian cancers with BRCA1 or BRCA2 mutations initially respond to platinum drugs.
  • However, acquired platinum resistance is a significant clinical challenge in these cancers.
  • Previous research identified secondary BRCA2 mutations restoring protein function in resistant BRCA2-mutated tumors.

Purpose of the Study:

  • To investigate whether similar secondary mutations in BRCA1 contribute to platinum resistance in BRCA1-mutated ovarian cancer.
  • To evaluate the role of BRCA1 genetic alterations in both acquired and primary platinum resistance.

Main Methods:

  • Analysis of nine recurrent BRCA1-mutated ovarian cancers treated with platinum compounds.
  • Sequencing of BRCA1 to identify secondary genetic changes in resistant tumors.
  • Immunohistochemical analysis to confirm restored BRCA1 protein expression.

Main Results:

  • Four of six platinum-resistant recurrent tumors showed secondary BRCA1 mutations restoring the reading frame.
  • None of the three platinum-sensitive recurrent tumors had BRCA1 sequence alterations.
  • Restored BRCA1 protein expression was confirmed in two cases with secondary mutations.
  • A case of primary resistance exhibited BRCA1 back mutation in the primary tumor and a secondary mutation in the recurrent tumor.

Conclusions:

  • Secondary mutations in BRCA1 can restore protein function and mediate platinum resistance in BRCA1-mutated ovarian cancer.
  • These findings highlight a mechanism of acquired resistance similar to that observed in BRCA2-mutated tumors.
  • Targeting mechanisms of resistance may improve treatment outcomes for ovarian cancer patients with BRCA mutations.

More Related Videos

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose13:04

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

Published on: October 14, 2015

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...